Wall Street analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report $27.26 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Enanta Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $23.97 million and the highest estimate coming in at $30.56 million. Enanta Pharmaceuticals reported sales of $10.42 million during the same quarter last year, which indicates a positive year-over-year growth rate of 161.6%. The company is expected to announce its next quarterly earnings report on Wednesday, February 14th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $27.26 million for the current year, with estimates ranging from $69.44 million to $97.28 million. For the next fiscal year, analysts expect that the company will post sales of $0.00 per share. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The firm had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. During the same period in the previous year, the business posted ($0.09) earnings per share. The business’s revenue for the quarter was up 491.3% compared to the same quarter last year.
Several institutional investors have recently bought and sold shares of ENTA. Stonepine Capital Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 165.9% in the second quarter. Stonepine Capital Management LLC now owns 492,265 shares of the biotechnology company’s stock worth $17,712,000 after acquiring an additional 307,166 shares during the period. Dimensional Fund Advisors LP lifted its stake in Enanta Pharmaceuticals by 34.3% in the second quarter. Dimensional Fund Advisors LP now owns 554,777 shares of the biotechnology company’s stock valued at $19,961,000 after buying an additional 141,688 shares during the period. Vanguard Group Inc. lifted its stake in Enanta Pharmaceuticals by 6.9% in the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock valued at $30,475,000 after buying an additional 54,856 shares during the period. Renaissance Technologies LLC lifted its stake in Enanta Pharmaceuticals by 9.3% in the second quarter. Renaissance Technologies LLC now owns 620,500 shares of the biotechnology company’s stock valued at $22,326,000 after buying an additional 52,807 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in Enanta Pharmaceuticals by 72.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 97,272 shares of the biotechnology company’s stock valued at $5,708,000 after buying an additional 40,853 shares during the period. 66.83% of the stock is currently owned by institutional investors.
Enanta Pharmaceuticals (NASDAQ:ENTA) opened at $65.78 on Thursday. The company has a market capitalization of $1,260.00, a P/E ratio of 82.23 and a beta of 0.64. Enanta Pharmaceuticals has a 12 month low of $25.92 and a 12 month high of $66.02.
COPYRIGHT VIOLATION WARNING: “Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $27.26 Million” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/18/enanta-pharmaceuticals-inc-enta-expected-to-announce-quarterly-sales-of-27-26-million.html.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.